PMID- 35795884
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230214
IS  - 2631-4797 (Electronic)
IS  - 2631-4797 (Linking)
VI  - 4
DP  - 2022
TI  - A Prospective, Open-Label, Multicenter, Real-World Study of VYC-17.5L Hyaluronic 
      Acid Dermal Filler in the Lips.
PG  - ojac047
LID - 10.1093/asjof/ojac047 [doi]
LID - ojac047
AB  - BACKGROUND: Hyaluronic acid (HA) injectable gels are used to define, enhance, and 
      volumize facial regions, such as the lips, a common treatment area. OBJECTIVES: 
      To evaluate the effectiveness and safety of the HA injectable gel Juvederm Volift 
      (Allergan, Aesthetics, an AbbVie Company Irvine, CA) with Lidocaine (VYC-17.5L) 
      for lip augmentation in real-world clinical practice. METHODS: This prospective, 
      open-label, multicenter study initially designed for 6 months, then extended to 
      12 months, enrolled adults with an overall grade of minimal to moderate on the 
      Lip Fullness Scale 2 (LFS2). Optional touch-up and repeat treatments occurred at 
      day 14 and month 12, respectively. The primary endpoint was a >/=1-point 
      improvement on the LFS2 at day 30. Other endpoints included improvements on the 
      FACE-Q Satisfaction with Lips questionnaire, Global Aesthetic Improvement Scale 
      (GAIS), subject assessment of natural look/feel of lips, and investigator 
      assessment of dynamic lip lines upon animation. Injection site reactions (ISRs) 
      and adverse events (AEs) were recorded. RESULTS: Of 60 subjects enrolled (mean 
      age, 36.8 years; 98.3% female), 59 were evaluable for efficacy at day 30; 13 
      (21.4%) received touch-up treatment. Thirty-six of 40 subjects completed the 
      extension study (month 12). LFS2 responder rates were 93.2% at day 30 (primary 
      endpoint) and 39.0% at month 12. Mean scores on the FACE-Q questionnaire improved 
      from baseline by 45.2 points and 23.6 points at day 30 and month 12, 
      respectively. Most subjects showed improvements on the GAIS. The majority of ISRs 
      were mild/moderate; no serious AEs occurred. CONCLUSIONS: VYC-17.5L was effective 
      and well tolerated for lip augmentation through 12 months posttreatment.
CI  - (c) 2022 The Aesthetic Society.
FAU - Demosthenous, Nestor
AU  - Demosthenous N
FAU - Eccleston, David
AU  - Eccleston D
FAU - Figueiredo, Vitor
AU  - Figueiredo V
FAU - Uva, Luis
AU  - Uva L
FAU - Kerson, Graeme
AU  - Kerson G
FAU - Silberberg, Michael
AU  - Silberberg M
LA  - eng
PT  - Journal Article
DEP - 20220515
PL  - England
TA  - Aesthet Surg J Open Forum
JT  - Aesthetic surgery journal. Open forum
JID - 101771713
PMC - PMC9252021
EDAT- 2022/07/08 06:00
MHDA- 2022/07/08 06:01
PMCR- 2022/05/15
CRDT- 2022/07/07 02:39
PHST- 2022/07/07 02:39 [entrez]
PHST- 2022/07/08 06:00 [pubmed]
PHST- 2022/07/08 06:01 [medline]
PHST- 2022/05/15 00:00 [pmc-release]
AID - ojac047 [pii]
AID - 10.1093/asjof/ojac047 [doi]
PST - epublish
SO  - Aesthet Surg J Open Forum. 2022 May 15;4:ojac047. doi: 10.1093/asjof/ojac047. 
      eCollection 2022.